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confirmed Mycoborterium genauense. No other specimens were MAC 
probe postive. The patient received a total of 19 months of therapy 
with clarithromycin, clofazamine and rifabutin, as well as ciprofloxin 
for the first 10 months. Although he tolerated the txeatment well 
and became asymptomatic, the knee arthrodesis did not completely 
fuse. 
Conclusions: Mycobacterium genuuense can cause PJI and should 
be suspected in culture negative cases with a positive AFB smear. 
-1 Epidemiological Features of Mycobacterias 
Isolated in a Tertiary Care Hospital (1994-1996) 
C. Pardo, M.J. Unzaga, I! Melero, E Calvo, C. Busto, R. Cisterna. 
Seruicio Minobiologia Hospital de Basurto, Bilbao, h q u e ,  Spain 
Objectives: Several studies in the literature have documented about 
of the resurgement of Tuberculosis in the last years. The purpose of 
this study was to evaluate the epidemiology of this disease in our 
hospital. 
Material and Methods: The Hospital of Basurto is a 800-bed 
general teachmg hospital that provides care to the urban area of 
Bilbao. We carried out a retrospective evaluation of patients with 
mycobacterias isolated between 1994-1996. 
Results: Mycobacterias were isolated in 392 patients with the 
follow distribution: 299 (76%) M tubprculosis (Mytu), 48 (12%) M 
kansasii (Myka) and 45 (1 1%) M auium. (Myai). 174 patients (44%) 
were mfected with HW. The number of patients infected was similar 
along three years. In 1994 (had been included the two last months 
of 1993): 157 patients; 1995: 102 patients; and 1996: 131 patients. 
There were dtfterences between sex: 270 males and 121 females 
(2/1 relation). The mean age of patients was 42 years (8 m-95 
y). The table shows the main characteristics of merent species of 
mycobacterias recovered. 
Mala Females HIV+ HIV- M. age 
299 - Myru 198 (66%) 100 (33%) 102 (34%) 197 (65%) 42 
48-Myka 37 (77%) 11 (23%) 30 (62%) 18 (37%) 45 
45-Myli 35 (77%) 10 (22%) 42 (93%) 3 (6.6%) 34 
Conclusions: (1) The number of isolations of Mytu in pa- 
tients HIV- is very important. (2) The male/female relation is 
increased between atypical mycobacteria (3/1) in comparison with 
Mytu (2/1). (3) The proportion of infected with HIV is increased in 
atypical mycobacterias. 
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Construction of an Internal Control for the 
Detection of Chlamydia pneumoniae by PCR in 
Asthma Patients 
D. Ursi, M. Ieven, H. Van Bever, H. Goossens. University Hospital 
Anttump, BeZgium 
Objectives: 1. To study the presence of C. pneumoniae in respiratory 
specimens by PCR. 2. To construct an internal control to monitor 
the efficiency of amplhcation in each reaction. 
Methods: For ampllfication of C. pneumoniae DNA, primers HL1 
and HRl 0. Clin. Microbiol. 3 0  434, 1992) were used. For the 
construction of the internal conh-ol, composite primers were syn- 
thesized TWICl and TWIC2, that started at their 5' end with the 
sequence of HLl and HRl, followed by sequences that were com- 
plementary to Herpes simplex type 2 DNA. Herpes simplex type 2 
DNA was ampMed with TWICl and TWIC2, folIowed by a sec- 
ond amplification using primers HLI and HR1. A 500 bp product 
was thus obtained that was purified, serially diluted and used as an 
internal control in each reaction since HLl and H R l  can be used 
to a m p w  both the internal control and C. pneumoniae DNA. Na- 
sopharyngeal aspixate collected during the winter period 1992-1993 
were analyzed by PCR after freeze-boiling iJ. Infect. Dis. 173: 1445, 
1996). Patients with a clinical diagnosis of asthma ( r 2  years of age, 
19 patients) or bmnchiolitis ( t 2  years of age, 56 patients) were se- 
lected. 
Results and Conclusions: Use of the internal control showed 
that about a quarter of the specimens contained inhibitors and had 
to be repeated after dilution. The use of an internal control is thus 
mandatory for the detection of false negative results. 
Our prehinary results indicate that the prevalence of C. pneu- 
m o n k  seems to be higher in the category of children with asthma 
older than 2 years of age, as compared to chddren with bronchiolitis. 
I P1267 I Serodiagnosis of Community Acquired 
Pneumoniae 
A. Agulla, J. Fernindez-Quintairos, M.I. Ursha, €? Sesma, 
J. Fernindez-Moraleja. Sm'cios de Microbiologah y Medicina Interna, 
Complex0 Hospitalario A. Marcide-Proj N. Santos, Fend,  Spain 
Objectives: Predence estimation of serodiagnosis to community 
acquired pneumoniae in the region of Ferrol (Galicia, Northwest 
Methods: Two pared sera specimens &om 185 patients aged 11 to 
90 years with diagnosis of community acquired pneumoniae attend- 
ing our Hospital from January 1995 to October 1996, were exam- 
ined for antibodies to Chlamydia pneumoniae, Legionella pneumophila, 
Coxiella burnetii and Mycoplasma pneumoniae. Antibodies to C. pneu- 
moniae, L. pneumophila and C. burnefii were determined by means of a 
rnicmimmunofluorescence assay and antibodies to M. pneumoniae by 
means of an agglutination assay. Serodiagnosis was confirmed when: 
a) seroconversion was detected or b) a title larger than 1/512 to C. 
pneumoniae and larger than 1/80 to M. pneumoniae were detected in 
the fmt serum. 
Results and Conclusions: Our serology battery was useful to 
diagnosticate 59 (30%) patients, 23 (12%) of C. pneumoniae pneumo- 
niae, 18 (10%) of L. pneumophila, 14 (7.5%) of M .  pneumoniae and 4 
(2%) o f C .  burnetii. 
Spain). 
EIA Assay for the Detection of legionella 
Antigen in Urine 
H. Sonneborn I ,  M. Backes ' , A. Hartlaub 
E Fehrenbach'. 'Biotest AG, Dreieich, Germany, 
2Robert-Koch-lnstitut, Berlin, Gomany  
Objectives: Development of an EM assay for the detection of Le- 
gionella antigen from all Legionella pneumophila serotypes in urine. 
Methods: An EIA assay was developed using polydonal rabbit 
antibodies specific for Legionella, but broadly crossreactive to all L. 
pneumophilia serogroups and some additional Legionella species. 300 
urines of healthy persons, 176 urines of persons with urinary tract 
infections, 46 urines of cultural proven cases of Legionella, 48 urines 
of suspected Legionellosis (without culture), 8 weakly positive urines 
from follow up samples of Legionellosis and 18 potentially cross 
reactive samples were tested. 
Resulk All 102 positive urines were detected as positive (10 
more than in a reference EIA). Only one of the urines from patients 
with UTI was weakly posltive giving a specificity of 99.8%. The 
J. Horn ', D. Jiirgens *, 
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mean OD of the positive samples was 2.2 times higher than the 
reference test, explaining the higher sensitivity 
Conclusions: The newly developed EL4 for Legionella urinary 
antigen is highly specific and highly sensitive. 
Fl Speciation of the Legionellaceae: An 
Evaluation of lntergenic rRNA Gene Sequence 
Length Polymorphism Analysis 
N.K. Fry, T.G. Harrison. Central Public Health hborafory, London, 
UK 
Objectives: To independently evaluate a published PCR-based 
method of Merentiation of the species (>40) comprising the genus 
Legionella using type and field strains. 
Methods: Legionella type strains, clinical and environmental iso- 
lates were cultured on standard media or in their amoebal host. 
Genomic DNA was extracted and the intergenic rDNA region am- 
plified. Following agarose gel electrophoresis, gels were stained with 
Ea r ,  and photographed. Registration of the electrophoretic pat- 
terns, normalisation of the images, grouping of st ra ins  and cluster 
analyses were performed using the sofhare package GelCompar 
(Applied Maths, Belgium). 
Results: The patterns generated were relatively simple and analy- 
sis of the type strains of Legionella species confirmed that most species 
could be Merentiated. Field strains were correctly identified to the 
correct species or species group as were new serogroups of previously 
described species. All isolates 6om amoebal hosts were distinct h m  
all other species tested. Isolates representing putative new species 
resulted in novel patterns. 
Conclusions: This method should provide reference laborato- 
ries with a valuable tool for identlfjlng field isolates of Legionella 
particularly non-pneumophila. However, modification of the o r i d  
protocol was necessary in order to standardise the methodology and 
increase its repmducibhty. 
m1 Clinical U t i l i i  of the Polymerase Chain 
Reaction in Aetiological Study of Community 
Acquired Pneumonia 
M. Salavert, R .  Menhdez ’, J. Cbrdoba, F? de la Cuadra I ,  
M*. Cremades ’ , J.L. L6pez-Hontangas, M. Gobermado. 
‘Departmentr of Microbiology and Respiratory Diseases, Hospital LA FE, 
Valenciu, Spain 
Objectives: To evaluate the aetiology of community-acquired 
pneumonia (CAP) using techniques of polymerase chain reaction 
(PCR). 
Patients and Methods: A prospective study was performed in 
98 consecutive patients admitted to a reference hospital. Pneumonia 
was dngnosed based on clinical and radiological findings. Microbi- 
ological evaluation comprised examination of respiratory specimens, 
blood cultures, and determination of acute and convalescent anti- 
body titers for L. pneumophila, M. pneumoniae, c .  pneumoniae, c. 
psittM’, C. burnetti and respiratory virus. PCR was used to exami- 
nate the presence of C. pneumoniae in h a t  swab specimen and of 
S. pneumoniae in blood. The aetiological dugnosis criteria for CAP 
were: a positive blood or pleural fluid culture, detection S. pneumo- 
nine-DNA in blood, the presence of IgM or a fourfold rise in IgG 
antibodies in paired samples. 
Results: Aetiological dngnosis was reached in 39 patients 
(39.7%): 20 S. pneumoniae (5 in blood culture, 1 in pleural fluid 
and 17 by PCR), 12 M. pnatmoniae, 2 C. burnetti, 2 I? amginosa, 
1 L. pneumophila and 2 influenza virus. S. pneumoniae in blood was 
detected by PCR in 17 patients (3 of them with positive blood 
culture), although in 2 patients with S. pneumoniae in blood PCR 
obtained was negative. In 11 patients DNA of C. pneumoniae was 
detected in throat swab, however in any patient a fourfold rise in 
titre in IgG was found. 
Conclusions: Detection of S. pneumoniae-DNA in blood in- 
creased &agnostic yield of CAP h m  5% using only blood culture 
to 17%, although in 2 patients PCR showed a false negative result. 
The presence of C. pneumoniae-DNA in throat swab samples without 
fdlf ihg criteria of acute infection, might be considered as remfec- 
tions or a prior infection that mght allow invasion by additionally 
bacteria. 
I P1271 1 Evaluation of an IIF Assay for the Diagnosis of 
Parainfluenza Wlus Type 3 Respiratory 
Infections 
V. Fernandez-Baca, J. Reina, I. Blanco. Virology Unit, Hospital Son 
Dureta, Palma de Mall~r~a, Spain 
We performed a prospective study of the usefulness of a n  indirect im- 
munofluorescence assay (IIF) (Monofluoht PI.3) as a rapid method 
and the shell-vial culture (LLC-MK2 cell h e )  in the diagnosis of res- 
piratory infections caused by the p d u e n z a  virus type 3 (PI-3). 
The samples were incubated at 36°C for 3 days and the vials were 
stained with the same monoclonal antibody used in the IIF assay. 
PI.3 was isolated in 31 (10.3%) of the 301 samples studied over a 
period of 8 months. The results obtained in the comparative study 
were as follows: 
IIF assay SVC No. (ss) 
+ + 23 (74.2) 
- 6 (19.3) + + - 2 (6.5) 
- - 270 
25 (80.6) 29 (93.5) 301 
The shell-vial culture was found to be superior to the IIF assay as 
a diagnostic technique. The merence was statistically signhcant (p 
= 0.01). The IIF may be used as a rapid screening method due to its 
high sensitivity, but the shell-vial culture should be used to confirm 
the &agnosis and to isolate the strains of parainfluenza virus h m  
clinical samples. 
I PI272 I Comparison Between MDCK, Vero, and MRC-5 
Cell Lines in the Isolation of Influenza A WNS 
J. Reina, c! Fernandez-Baca, M. Munar. Virology Unit, Hospital Son 
Dureta, Palma de Mallorca, Spain 
We compared the efficacy of various cell lines in the isolation of 
63 (8.4%) Influenza A virus in 746 respiratory samples. All samples 
were inoculated in the MDCK, Vero and MRC-5 cell lines, using 
the shell-vial technique, and incubated at 36°C for 3 days. The vials 
were stained with a speufic monoclonal antibody (clone IA 52). The 
results obtained were as follows: 
Cell h c s  
MDCK Vcro MRC-5 No ( “ 7 )  
+ f + 36 (57.1) 
+ f - 9 (14.3) 
+ 18 (28.6) 
63 (100) 45 (71.4) 36 (57.1) 63 
- - 
Only the MDCK cell line enabled us to isolate all the strains of 
Influenza A. Statistical Merences were obtained when comparing 
MDCK cell line with the Vero (p < 0.001) and the MRC-5 cell 
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lmes (p < 0.001) for quahtative and quantitative sensitivity. The 
MDCK cell line s t i l l  provides the hghest diagnostic yield in the 
isolation of the Influenza A virus h m  c h c a l  samples. 
m1 Fractal Approach to the Evaluation of Sensitive 
Cells interaction with the Viral Particles 
A.I? Fedtchouk', AS. Fedtchouk. 'Odessa Research Institute of 
Virology ti Epidemioloa, Odessa, Ukraine, Odessa State University, 
Physical Department, Odessa, Ukraine 
Objectives: The promotion of new physical techniques application 
to the d infectious processes dynamics evaluation. 
Methods: We have proposed the original method of low-power 
laser beam f f i c t i o n  on the thin layers of white mice lungs under 
the experimental influenza A0/32 infection. We have compared the 
Qctal dimension of the samples of animal lungs cured and non-cured 
with unithiohm. The viral particles as well as their nearest neigh- 
bourhood play the role of the optical inhomogeinity and, in such a 
way, the centres oflaser beam difhction. We have also controlled the 
mfectious activity of the lungs with the use of the standard methods 
of titration. As well we have determined the enzymatic activity of 
the proteolytic systems of lungs preparations. 
Results: The fi-actal dimension of the f f i c t i o n  pattern is being 
proportional, as it was shown experimentally, to the titration grade of 
the certain stage of the mfectious process. It was discovered that the 
linear regression interrelation exists between the hctal dimension 
of the d&action pattern and the titration grade of the d mfec- 
tious process at the any possible given moment of the early stage of 
virus-cell interaction, Using the proposed method we have shown 
that the unithlolum plays the role of active protector of the sensitive 
cells at the early stages of the d mfectious process. 
Conclusions: By means of the direct optical experiment we have 
shown that the method of the fi-actal analysis of the ddEaction pat- 
terns can be of great use in the evaluation of the new medicine 
d u e n c e  on the rate of @e infectious processes dynamics without 
any strong dependence on the real nature of the virus itself and is ap- 
plicable to the testing process of Werent new m e d d  preparations. 
I PI 274 Acute Exacerbations of Chronic Bronchitis 
(AECB) in Out-Patients: Sparfloxacin (SPFX) vs 
Roxithromycin (ROXI) 
D. Kohler ', P Kemper ' , M. Moller for the Study Group. ' Clinic 
Kloster Grajichaft, Schmallenberg, Germany, 'Hanau, Germany 
Objectives: To compare the efflcacy and safety of SPFX and ROXI 
in the treatment of AECB in out-patients. 
Methods: In a double-blind, multicentre study performed in 
Germany, 248 adult out-patients with AECB received either SPFX 
400 mg on day 1 then 200 mg qd for a duration of 5 days (d) or 
ROXI 300 mg qd for 7 d. Clinical signs and symptoms and bac- 
teriological results were evaluated at inclusion (Vl), at the end of 
treatment (V3) and 3-4 weeks h e r  V3 (V4). 
Results: The clinical success rates and number of relapses were: 
SPFX 5 d ROXI 7 d CI 90 1-B 
ITT V3 102/120 (85.0%) 107/126 (84.9%) [-7.6% 7.4%] 70.8% 
PPA V3 92/106 (86.8%) 100/111 (90.1%) [-3.8% 10.4%] 74.5% 
Relapse V4 4/91 9/98 
~ ~ ~~ 
ITT = mtenuon-to-treatment analyur, PPA = per-protocol andysu, CI 90 = 90% c o d -  
dence mtcrvd of A between success at-, 1-p = power 
The most fiequently isolated pathogens were H .  influenzap (n = 
27), H .  parainzuenzae (n = 63), S. pneumoniae (n = 9). At V3, eradi- 
cation or presumed eradication was achieved for 48/53 (90.5%) and 
41/55 (74.5%) evaluable pathogens in the SPFX and ROXI group, 
respectively. In the SPFX group, 21 patients reported 34 adverse 
events (AE), most fiequently rash (includmg 2 cases of presumed 
mdd phototoxicity) (n = 4); in the ROXI group, 27 patients re- 
ported 43 AEs, most fxequently nausea (n = 6). 
Conclusions: Although the number of included patients is less 
than originally planned (n = 400). the clinical efficacy and safety 
of SPFX 400/200 mg during 5 d and ROXI 300 mg during 7 d 
seems to be slmilar; there is a strong evidence of microbiological 
superiority of SPFX. 
LP1275 1 Treatment of Community Acquired Pneumonia 
(CAP): Comparison of Sparfloxacin (SPFX) vs 
Clarithromycin (CLAR) 
J. Schauer', A.C. Rodloff' for the Study Group. 'Univerrily Clinic, 
University Leipzig, Gemany, 'Med. Microbiology, University Leipzig, 
Germany 
Objectives: To compare the efficacy and safety of SPFX and CLAR 
in the treatment of CAE! 
Methods: In a double-blmd, multicentre study performed in 
Germany, 84 hospitalized patients with CAP received either SPFX 
400 mg on day 1 then 200 mg qd (n = 43) or CLAR 500 mg bid 
(n = 41) for 7-14 days. Results were based on both the evolution 
of c h c a l  signs and symptoms and of X-ray findings at the end of 
treatment (V3) and 3-5 weeks after V3 (V4). 
Results: Patients with cknical success vs total enrolled patients 
were as follows: 
SPFX C U R  
ITTV3 36/43 36/41 
PPAV3 35/37 32/34 
PPAV4 29/30 26/27 
ITT = intention-to-treatment malyus, PPA = per-protocol analyslr 
The most fkquently identified pathogens were S. pneumoniae (n = 
16), H .  inzuenzae (n = 7), streptococci (n = 5) and C. pneumoniae (n 
= 5). In the SPFX group there were 32 adverse events (AE) reported 
in 16 patients, most fkquently cutanous rash (n = 4, incl. 1 case of 
mild phototoxicity). In the CLAR group 33 AEs, most fkequently 
an increase ofhepatic enzymes (n = 5), were observed in 21 patients. 
Conclusions: The efficacy and de ty  of SPFX and CLAR in the 
clinical trial appears high, however a comparison of clinical success 
rates is not feasable due to its low statistical power. 
I PI276 I Acute Exacerbations of Chronic Bronchitis in 
Hospitalized Patients: Sparfloxacin (SPFX) vs 
Ciprofloxacin (CPFX) 
H. Lode I ,  R. Wettengel, E Vogel, G. Marklein for the Study 
Group. ' City Hospital Zehlendorf; Berlin, Germany 
Objectives: To compare the efficacy and safety of SPFX vs CPFX 
in the treatment of AECB in hospitalized patients. 
Methods: In a double-blind, multicentre study performed in 
Germany, 165 adult patients with AECB recewed either SPFX 400 
mg on day 1 then 200 mg qd for 8 days (d) or CPFX 500 mg 
bid for 10 d. Clinical signs and symptoms and bacteriological results 
were evaluated at inclusion (Vl), at the end of treatment (V3) and at 
follow-up 7-14 d after V3 (V4). 
Results: The clinical success rates and number of relapses are 
shown in the table. The most kequently isolated pathogens were H. 
injuenzae (n = 19), H. parainzuenzae (n = 16), S. pneumoniae (n = 
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SPFX 8 d CPFX 10 d CI 90 1-B 
1l-r v 3  73/83 (88.0%) 69/81 (85.2%) [-11.5%,6.0%] 59.73 
PPA V3 64/68 (94.1%) 63/67 (94.0%) [-6.8%; 6.6%] 79.3% 
RelapseV4 3/47 5/51 
I T T  = intcnnon-to-treatment a d y m ,  PPA = per-protocol analysis, CI 90 = 90% confi- 
dence m t e d  of A between success rates. 1-8 = power 
11). In the SPFX p u p  there were 36 adverse events (AE) reported 
in 26 patients, most kquently an increase of hepatic enzymes (n = 
6), insomnia or sleeplessness (n = 5). In the CPFX group 35 AEs 
including nausea (n = 4), insomnia or sleeplessness (n = 4) were 
observed in 24 patients. No case of phototoxicity was reported. 
Conclusions: Although the number of included patients was less 
than planned (n = 200), the dinical efficacy and safety of SPFX 
400/200 mg during 8 d and CPFX 500 mg bid during 10 d were 
equivalent in the evaluable population with an acceptable power. 
1 P I  277 I Threeday Therapy with Azithromycin in 
V. Nonikov, 0. Makarova, Y. Kopylev, V. Minaev, I. Rytchik. 
Central Clinical Hospital, Moscow, Russia 
Objectives: To assess the effectiveness and safety of 3-day therapy 
with azythromycin in bacterial pneumonia. 
Methods: Forty nine subjects entered t h ~ ~  open-label compar- 
ative randomized study. Twenty six subjects received azithromycin 
(A), and 23 - amoxicillin/clavulanic acid (CA). Clinical, roentgeno- 
logical, and bacteriological findings were assessed. The antibiotics 
were administered orally: 500 mg A once a day for 3 days, or 625 
mg CA t.i.d. for 10 days. 
Results: Clinical effect was observed in all A subjects, while CA 
had to be replaced with another antibiotic because of lacking ef- 
fect in 2 subjects. CA was discontinued in 4 subjects because of 
allergic reactions. X-rays taken on 9-1 Ith days of the study showed 
pneumonia to have completely resolved in 24 (92.3%) subjects of A 
Group and in 15 (88.2%) of CA Group. Bacteriological effectiveness 
was 96% in A Group and 94% in CA Group. 
Conclusions: Three-day therapy with 500 mg A once a day 
and 10-day therapy with 625 mg CA t.i.d proved to be of s& 
effectiveness. Frequency of side effects was hgher (p = 0.02) in CA 
group. 
Bacterial Pneumonia 
I PI 278 I Aziihromycin in the Treatment of Q Fever 
I. Kuzman 
' U n i m i t y  Hospital of Infertious Diseases; Zagreb, Croatia, 'Pliva d.d. 
Pharmaceutid Division; Zagreb, Croatia 
Objectives: Retrospective study was undertaken in order to assess 
the efficacy and safety of azithromycin in the treatment of Q fever. 
Methods: Sixty four patients with atypical pneumonia and sero- 
logical (CF) evidence of Coxiella burnetii infection were hospitalized 
in our institution over 4 years. Among them 22 were treated with 
azithromycin (in a total dose of 1.5 g given over 5 or 3 days), 15 
with doxycydine (100 mg bid for 10-14 days), and 15 with other 
antibiotics or antibiotic combinations. The remaining 12 patients 
were excluded from analysis since they received effective antibi- 
otics (macrolides, tetracycline or quinolones) prior to hospitaliza- 
tion. Study groups were comparable with respect to demographic, 
case history, clinical and laboratory data. Cure was defined as disap- 
pearance of fever within 96 houn after the initiation of treatment 
with regression of infiltrate on control chest X-rays. 
K. OreCkovit ', S. Schonwald ', J. &dig ', T. Zrnit '. 
Results: All patients treated with azithromycin were cured. The 
average duration of fever after treatment initiation was 2.5 days in 
azithromycin-treated p u p .  It w x  skghtly shorter in doxycycline 
group (2.0 days), but notably longer in patients receiving other an- 
tibiotics (3.4 days). Azithromycin was well tolerated, and no side 
effects was observed. 
Conclusion: Azithromycin, given in a total dose of 1.5 g over 3 
or 5 days, is effective and well tolerated in the treatment of Q fever. 
I P I  279 1 Aziihromycin: Single 1.5 g Dose for Atypical 
S. Schonwald 
J. &g2, K. Orekovit'. 'University Hospital oflnfectiour Diseases; 
Zagreb, Croatia, 'Pliva d.d. PharmaceuticaLr Division; Zagreb, Croatia 
Objectives: To assess the efficacy and safety of single dose 
azithromycin in the treatment of community-acquired atypical pneu- 
monia. 
Methods: The study was open and comparative. A total of 100 
adult patients with atypical pneumonia syndrome were randomized 
to receive azithromycin as a single 1.5 g dose, or 500 mg once daily 
for 3 days. The presence of Mycoplacma pneumoniae, Chlamydiapsittaci, 
Coxiella burnetii, and Legionella pneumophila infection was dngnosed 
by serological tests. Control clinical examinations were pedormed 72 
hours, 10-12 days and 4 weeks after treatment initiation. Cure was 
defined as disappearance of fever within 72 hours after treatment 
initiation with &appearance of other clinical signs of pneumonia 
and complete or partial regression of X-ray abnormalities withm 2 
weeks. 
Results: Among 96 patients (48 in each p u p )  who were evalu- 
able for clinical efficacy M. pneumoniae infection was confirmed in 
26, C. psittan' in 5, C. burnetii in 6, and L. pneumophila in 4. All 
patients but one were cured. Single dose azithromycin failed in one 
patient, due to vomibng and diarrhea after dosing. Side effects were 
also observed in one patient in 3-day group. Mild, transient in- 
crease of liver enzymes was observed in 4 patients in each group, 
and eosinophilia in 1 and 2 patients in single dose, and 3-day group, 
respectively. 
Conclusion: Single 1.5 g dose of azithromycin may be an alter- 
native to standard 3-day azithromycin regimen in the treatment of 
outpatients with atypical pneumonia syndrome. 
Pneumonia 
I. Kuzman ', V skerk ', V. Car ', V Burek ', 
p] Efficacy of Ditithromycin in 2000 Patients with 
Acute Bronchitis and Acute Exacerbation of 
Chronic Bronchitis 
H. Riemer, W. Wein. Deparhent ofPulmonoZogy, University Hospital 
Vienna, Austria, Eli Lilh Austria 
Objectives: To investigate the impact of Dirithromycin in the rou- 
tine setting. 
Methods: 500 mg ofDirithromycin, a novel macrolide antibiotic 
with a long half-life time and high bronchial tissue concentrations 
were given once dady for 5 days in thts national Austrian experience 
study with 2002 patients, suffering fiom acute bronchitis (75%), or 
acute exacerbation of chronic bronchitis/AECB (25%). 
Results: clinical response, evaluated after seven days: 
n = 1995 Cured Improved Intemudhte Fdurc 
Acute bronchus 63% 2% 6% 2% 
AECB 21% 62% 15% 2% 
Global judgement of therapeutic success by physician after seven 
days: 
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n = 1975 Clear success Intermcdutc Urnahsfactor\. 
Acute bmncluw 8856 1096 2% 
AECB 79% 18% 3% 
Dirithromycin therapy compared with previous antibiotic therapy 
~ ~ ~~ 
n = 155 Defitlltcly bcacr Better E q d  Wonc 
Acute bronchim 33% 
AECB 32% 
40% 25% 2?4 
44% 22% 2% 
Only 72 patients (4%) experienced adverse events, non-serious, 
(mostly GI-tract). 
Conclusion: Five day therapy of acute bronchitis or AECB with 
Dirithromycin 500 mg once daily is associated with an overall re- 
sponse rate of 98% and a 4% incidence of mild side-effects. 
[p12811 A Randomized, Mutticenter Study to Compare 
the Efficacy and Toleration of Azithromycin and 
Clarithromycin in the Treatment of Adults with 
Mild to Moderate Community-acquired 
Pneumonia 
B. O'Doherty Grey, Counfy WeX&rd, Wexford, Eire, UK 
In a multicenter, open-label, comparative study, adult outpatients 
with mild to moderate community-acquired pneumonia, diagnosed 
by positive chest X-ray, were randomized to treatment with either 
azithromycin (500 mg once daily for 3 days) or clarithromycin (250 
mg twice daily for 10 days). Patients were clinically assessed on days 
3-7 and 12-16. Those patients who were classed as improved at 
day 12-16 were also evaluated on day 19-23. A total of 203 pa- 
tients (range 12-78 years) were randomly assigned to treatment (101 
azithromycin, 102 clarithromycin). Of these, 176 (88 azithromycin, 
88 darithromycin) were clinically evaluable. The most common rea- 
son for exclusion was thk absence of a confirmed diagnosis at baseline 
( s ix  azithromycin, five clarithromycin). Satisfactory dinical response 
(cure + improvement) was recorded at the end of therapy in 83/88 
(94%) azithromycin and 84/88 (95%) clarithromycin patients (p = 
0.518). At day 19-23, only one patient in each treatment group had 
relapsed. Bacteriological eradlcation was reported for 31/32 (97%) 
of the pathogens isolated in the azithromycin and 32/35 (91%) in 
the clarithromycin group. Incidences of treatment-related adverse 
events were sirmlar for the two groups (p = 0.815), and gastrointesti- 
nal adverse events were reported in seven (7%) azithromycin- and 
eight (8%) clarithromycin-treated patients. Two (2%) darithromycin 
patients discontinued therapy due to severe adverse events. No pa- 
tients in the azithromycin group discontinued treatment as a result 
of adverse events. 
Conclusion: 3-day, once-daily administration of azithromycin 
is as clinically effective and well tolerated as 10-day, twice-daily 
darithromycin in the treatment of mild to moderate commu- 
nity-acquired pneumonia. 
I P1282 I Azithromycin (AZM) vs. Co-Amoxiclav (CAMX) 
in Patients with Lower Respiratory Tract 
Infections (LRTI) 
M. Rossi I ,  B. Ramsperger *, M. Altwegg 3 ,  A.U. Gerber 
'RegionaLpital Bid,  Switzerland, ' e z e r  AG Zurich, Switzerland, 
3Meded. Microbiology, Uniuefiity $Zurich, Switzerland 
Objectives: To elucidate a) efficacy and safety of AZM qd X3 vs 
CAMX tid ~ 1 0 .  b) spectrum of pathogens in LRTI. 
Methods: Open, randomized, comparative study in 13 cen- 
ters in Switzerland. Patients with community acquired pneumonia 
(CAP) or acute exacerbation of chronic obstructive pulmonary dis- 
ease (COPD) (Anthonisen Type I) were treated with AZM 500 mg 
qd x 3 or CAMX 625 tid x 10. Evaluation of pathogens included 
bacterial cultures, PCR for Chlamydia pneumoniae and Mycoplasma 
pneumoniae and serology for M. pneumoniae, Legionella spp., Chlamy- 
dia pneumoniae and viruses (influenza A and B, RSV). 
Results: Of 109 patients (CAP: 96; COPD: 13) 51 received 
AZM, 46 CAMX. Cure and improvement was reported in 98% 
for both treatments. There was one failure (AZM) and one relapse 
(CAMX). Eradication was noted in 33 of 44 bacteriologically evalu- 
able patients (14 AZM, 19 CAMX), superinfection/partial e b a -  
tion in one each. In seven clinically cured patients, PCR remained 
positive for M. pneumoniae. Side-effects (mainly to digestive tract): 
15/46 in CAMX and 9/63 in AZM-patients. Seven patients discon- 
tinued treatment (1 AZM, 6 CAMX). 
Conclusions: Pathogens were idenafiable in more than 40% of 
patients: predominantly S. pneumoniae, M.  pneumoniae, H. injuenzae 
and C. pneumoniae. C h c a l  and bacteriological cure was observed in 
the vast majority of cases without any significant Werence between 
the two study groups. AZM 500 qd x 3  appears to be a valuable 
alternative treatment for patients with lower respiratory tract mfec- 
tions. 
Ip12831 Comparative Double Blind Study of Oral 
Cefotiam Hexetil Versus Amoxicillin/Clavulanic 
Acid in Acute Otitis Media 
€? Gehanno', €? Sednaoui2, S .  Nisse-Durgeat'. 'C.H.U 
Bichat-Claude Bernard, Paris, France, 'Insritut A@ed Fournier, Paris, 
France, 3Laboratoires Takeda, Puteaux, France 
Objectives: This multicenter study compared the efficacy and the 
safety of cefotiam hexetil (CH) 200 mg bid to those of amoxi- 
cillin/clavulanic acid (AMC) 1 g bid for a 10 day treatment in acute 
otitis media. 
Methods: One hundred and eighty nine ambulatory patients 
(mean age = 41 years old f 15) with acute otitis media were ran- 
domly allocated either to CH (96 patients) or AMC (93 patients). 
Twelve patients (CH = 8, AMC = 4) with a chronic otitis media 
were excluded and 177 patients were analyzed for the efficacy (CH 
= 88, AMC = 89). Both groups were comparable at the inclusion. 
30% of patients had a Collection Stage (CS) and 70% a Spontaneous 
Perforation Stage (SPS). We defined as undeniable acute otitis meha, 
those with germs isolated by paracentesis and those with spontaneous 
otorrhea and germs like S. pneumoniae or H. injuenzae @oup I). 
Results: In the first group (61 patients) = chical cure was 97% 
in CH group vs 100% in AMC group. In the other cases, a doubt 
concerning the hagnosis persists in spontaneous otorrhea with com- 
mensal germs (I! aeruginosa and S. aunus) even if the patients had a 
restoration of their tympanum (group 11). In the second group (113 
patients) = cknical cure was 92.5% in CH group versus 85% in AMC 
group. The evolution of the clinical signs were comparable in both 
groups. Adverse events ( d y  digestive &orders) were comparable 
in both groups (14% versus 10%). 
Conclusion: Cefotiam hexed is as effective and as well tolerated 
as amoxicillm/clavulamc acid in the treatment of acute otitis media. 
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1 P I  284 I Direct Demonstration of Chlamydia 
p. Sednaoui I ,  0. Patey *, J. T r o t o ~ ~ ,  H. M C c h  ', D. Ponsonnet ', 
pneumoniae in Angina 
A. Bianchi I .  'Instifuf A 9 e d  Fournier, Paris, France, 'HGpital de 
Mlleneuve Sainf Georges, France, 3HGpital Boucicaut, France, 4FDM 
Pharma, Paris, France, 5 A b b ~ t t  Division Pharmacie, Rungis, France 
If the role of Chlamydia pneumoniae (C.p.) in acute respiratory cksease 
is well established, little is known about the association of C.p. and 
angina. Six hundred and eighty four patients aged from 18 to 97 
years consulting general practitioner for angina from May to August 
1996 entered the study. Two throat swabs were collected by the gen- 
eral practitioner. One was tested for duect detection of chlamydial 
antigen (Test pack Chlamydia@ Abbott), the other was discharged 
in sucrose phosphate buffer (2SP) transport medium for cell (HL 
and HeLa 229) culture and for PCR &.A. Campbel). Hundred and 
forty six results were questionable by cell culture isolation (21.3%) 
and were considered as negative after two serial passages. As shown in 
the table, C.p. could be detected by PCR. These results revealed the 
presence of C.p. DNA in the throat of 1.3% of the patients sufTering 
h m  angina, but without etiologic evidence. 
PCR negative PCR pmiuvc 
Anngen negzuvc 543 4 
hugen undcteruuned 90 0 
Anngen porlnvc 42 5 
I P I  285 I Synergistic Activity of Antibiotic Combinations 
against Chlamydia pneumoniae 
C. Wolf, R. Malinverni. Med. Policlinic, InseLpifal and Abteilung 
Klinisch-Erpm'mentelle Forschung, Universitiit Bern, Sruitzerkand 
Objectives: To investigate the in vitro activities of combinations of 
antibiotics against C. pneumoniae s t r a i n  AR-39. 
Methods: Azithromycin (Az, supplied by Pfizer Research, 
Corn.), doxycycline (Dox) and rifampin were used. Suscepti- 
bility tests were done in HL cell cultures. Three culture vials were in- 
oculated with strain AR-39 (2 x lo5 inclusion forming units [IN] 
per vial) and the drugs were added at Merent submbibitory concen- 
trations. After 3 days, the vials were stained for inclusion counts with 
a genus-specific monoclonal antibody (CF-2). The minimum in- 
hibitory concentrations (MIC), the lowest antibiotic concentrations 
showing no inclusions by CF-2 staining, were determined previously 
by serial dilutions of the test drugs. 
Results: The MIC's of Az, Dox and Fbf were 0.1, 0.05 and 
0.0075 Wg/d respectively. The Table shows the Log 10 decrease of 
IFUs in cells after exposure to the single agents and the combinations 
when compared to controls. 
~~~ ~ 
Conc (x MIC) Conwls(Log1FU) Rf  Az Dox Dox+&f AzcDox Az+M 
0.58.1 0.1 1.2 0 1.5 2.7 2.7 
0.68.1 0.3 1.5 0 1.6 2.9 3 
0.88.1 0.6 1.9 0.5 2.2 3.5 3.9 
Conclusions: While Dox and W a s  single agents did not show 
antichlamydial activity at subinhibitory concentrations, Az exhib- 
ited some inhibition of growth. Combinations including Az showed 
substantial activity against AR-39 at subinhibitory levels. 
Meningitis: Epidemiology and complications 
-1 Analysis of Bacterial Meningitis Infections in 
S. Tyski, W Grzybowska. D u g  Institute, Warsaw, Poland 
In Poland the bacterial and viral meningtis infections are compul- 
sory registered according to WHO rules. Most of the bacterial cases 
are characterised by clinical symptoms, and real number ofinfections 
confirmed by pathogen isolation is unknown. All bacterd but N. 
meningitidis cases, without further characterisation, are registered in 
one p u p  of purulent mfections. 
The aim of this study was to recognise the amal situation in 
Poland and performe some retrospective analysis. The specialy pre- 
pared questionaire was send to hospitals in merent part of Poland, 
where the patients sdering h m  meningitis are hospitalised, in or- 
der to get information about the most common bacterial strains 
isolated h m  cerebrospinal fluid (CFS). The data collected between 
1992-June 1996 from 47 hospitals allowed to indicate N. meningitidis 
(18.3%), S.  pneumoniae (9.6%), H. influenzae (5.6%) and S. epider- 
midis? (22.1%) as the main isolates of CSE Strains of other merent 
species were isolated less fkquently. The presence of saprophyac 
staphylococci amongst most common isolates shows poor level of 
CSF collection in Poland. Ninty five A? meningitidis, 38 S. pneumoniae 
and 28 H. influenzae type b strains isolated from CSF were also sent 
by collaborators for further characterisation. The antibiotic sensitiv- 
ity of these strains to selected antimicrobial agents was determineted. 
Betalactamase production by H .  inzuenzae and meningococcal strains 
was also checked. No one analyzed isolate was resistant to penicillin 
according to NCCLS. 
Poland in Years 1992June 1996 
I P I  287 1 Reculrent Bacterial Meningitis-Etiology and an 
Approach to Therapy 
V. Twkulov, N. Made-Samardkija. J. Vukadinov, G. can&. Clinic 
for Infecrious Diseases, Medical Faulty, University ofNovi Sad, Yugoslavia 
Recurrent meningitis represents the repeated episodes of the acute 
meningitis, hence its outstanding importance. The aim of the study 
had been to investigate the clinical features as well as the etiology and 
the therapeutic procedures used in curing the patients with recurrent 
meningitis. 
At our clinic 4 patients had been treated for recurrent bacte- 
rial meningitis during the 1991-1995. period. All the patients were 
masculine, the youngest 12 years old, the others adult. One of the 
patients had the purulent meningitis 2 times, 2 patients 3 times, and 
one patient even 4 times. In all the patients the cause of the illness 
was Sfreptocorn pneumoniae, except in one case where Pneumococcur 
was isolated 3 times and Neisseria meningitidis once. Chemocultures 
were negative in all patients. In all cases the traumatic anatomical 
defect of the hard brain membrane (durae mater) was found. At the 
admittance the state of the patients had been diflicult, two of them 
in coma, and one artificially ventilated. 
Causal therapy was conducted by the parented application of 
high doses of antibiotics. The combinations of crystalline penicillin 
and chloramphenicol, ceftriaxone and chloramphenicol and in one 
case penicillin and cefotaxim were used. 
The outcome ofthe cure was satisfactory in all patients. They were 
discharged from the clinic and recommended for surgical treatment 
to mend the defect of the durae in order to suppress the repeating of 
the bacterial meningitis. 
